Cart
sales@molnova.com
RRX-001
CAS No. 925206-65-1
RRX-001 ( RRX001;RRX 001 )
Catalog No. M16629 CAS No. 925206-65-1
RRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 63 | In Stock |
|
| 5MG | 105 | In Stock |
|
| 10MG | 140 | In Stock |
|
| 25MG | 264 | In Stock |
|
| 50MG | 462 | In Stock |
|
| 100MG | 673 | In Stock |
|
| 500MG | 1404 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRRX-001
-
NoteResearch use only, not for human use.
-
Brief DescriptionRRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity.
-
DescriptionRRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity; targets CD133 + /CD44 + cancer stem cells from colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc; inhibits HCT 116 and decreases levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner; RRX-001 (RRX001) is a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia.Lung Cancer Phase 2 Clinical
-
SynonymsRRX001;RRX 001
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number925206-65-1
-
Formula Weight268.02
-
Molecular FormulaC5H6BrN3O5
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL 373.11 mM
-
SMILESO=[N+](C1([N+]([O-])=O)CN(C(CBr)=O)C1)[O-]
-
Chemical Name2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Reid T, et al. Lancet Oncol. 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3.
2. Scicinski J, et al. Redox Biol. 2015 Aug;5:422. doi: 10.1016/j.redox.2015.09.035.
3. Kim MM, et al. Transl Oncol. 2016 Apr;9(2):108-113.
4. Oronsky B, et al. Invest New Drugs. 2016 Jun;34(3):371-7.
2. Scicinski J, et al. Redox Biol. 2015 Aug;5:422. doi: 10.1016/j.redox.2015.09.035.
3. Kim MM, et al. Transl Oncol. 2016 Apr;9(2):108-113.
4. Oronsky B, et al. Invest New Drugs. 2016 Jun;34(3):371-7.
molnova catalog
related products
-
Dihomo-γ-Linolenic a...
Dihomo-γ-Linolenic acid methyl ester is the methyl ester form of Dihomo-γ-Linolenic acid which has anti-inflammatory and anti-proliferative effects.
-
Chicoric acid（b）
Cichoric acid has been shown to inhibit hyaluronidase and HIV-1 integrase, and to possess phagoeytosis stimulatory activity in vitro and in vivo and antiviral acitivy.
-
MARCKS Peptide(151-1...
Myristoylated Alanine-Rich C Kinase Substrate peptide (151-175) is a high affinity Protein Kinase C substrate.
